Attorneys for a family of Diep An told a Baltimore jury earlier this month that Takeda executives hid the link between Actos and cancer, and failed to warn the public about the risk for six years.
An’s family is suing Osaka, Japan-based Takeda for the death of Diep An, who died from bladder cancer. An’s case is the second of 3,000 to come to trial, according to Bloomberg BusinessWeek.
A study last year in the Journal of the National Cancer Institute found that patients taking TZD (thiazolidinedione drugs, including Actos and Avandia) for more than five years had two to three times the incidence of bladder cancer as patients taking sulfonyurea (diabetes medication).
The study was performed by University of Pennsylvania researchers and is yet another link in the chain between bladder cancer and Actos.
Ronac Mamtani, MD, the head University of Pennsylvania researcher said that the stated that, “doctors who care for patients with diabetes should be very aware of any bladder-related symptoms patients might be having, like blood in the urine, and take steps to further evaluate those issues.”
For questions about the Actos litigation, please contact 888-883-2299, or info@sheller.com.
The Legal Examiner and our Affiliate Network strive to be the place you look to for news, context, and more, wherever your life intersects with the law.
Comments for this article are closed.